[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
January 1969

Regulation of Erythropoiesis in Erythroleukemia

Author Affiliations

FACP; FACP, Philadelphia

From the Cardeza Foundation for Hematologic Research, Department of Medicine, Jefferson Medical College, Philadelphia.

Arch Intern Med. 1969;123(1):60-63. doi:10.1001/archinte.1969.00300110062012

DiGuglielmo1 recognized that erythroid cell maturation was distinctly abnormal in certain neoplastic conditions of the bone marrow. In the most usual variety, referred to as erythroleukemia, an abnormal myeloblastic proliferation is combined with disordered megaloblastic erythroid maturation often leading terminally to typical acute myeloblastic leukemia. In other forms, the disorder may assume either a more chronic and nonprogressive course or a more rapid and fulminant course involving chiefly the red blood cell precursors.

Normal erythroid tissue is regulated by the hormone erythropoietin, which is produced in response to the need for an increased number of circulating red cells. The report to follow describes a patient with erythroleukemia who was investigated with the objective of determining whether "neoplastic" erythroid tissue behaves in an autonomous and unregulated fashion. By several parameters of measurement, erythropoiesis in this patient was found to respond to alterations in concentration of plasma erythropoietin.

Patient Summary